myLaurel® | $12,000,000 | (Jun 4, 2025)
Matterworks | Undisclosed Amount | (Jun 4, 2025)
Ciroos | $21,000,000 | (Jun 4, 2025)
Certified by Founder
Lodge
ProJenX
start up
United States
- New York, NY
- 03/11/2023
- Series A
- $15,000,000
ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.
- Industry Biotechnology Research
- Website https://projenx.com/
- LinkedIn https://www.linkedin.com/company/projenx-inc/about/
FISPAN | $30,000,000 | (Jun 4, 2025)
Volare Solutions | $29,578,562 | (Jun 4, 2025)
Skyral | $20,000,000 | (Jun 4, 2025)
Compyl | $12,000,000 | (Jun 4, 2025)
Veris AI | $8,500,000 | (Jun 4, 2025)
Clara(US) | $3,100,000 | (Jun 4, 2025)
Akadeum Life Sciences, Inc. | $20,000,000 | (Jun 4, 2025)
ProteinQure | $11,000,000 | (Jun 4, 2025)
Trustifi | $25,000,000 | (Jun 3, 2025)